The Pharmaceutical Index

2013 Worldwide NCEs

Ltd. Pharmacodia (Beijing) Co.

$96.99

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

CRC Press
14 October 2024

Medical research; Pharmacology; Chemistry; Life sciences: general issues; Pharmaceutical technology

An ideal drug candidate should possess good pharmacological activity, absorption, distribution, metabolism, excretion and toxicity properties. Historically, there are around 6,000 drugs being used in humans and approximately 3,000 still in clinical use, not including herbal medicines. This Pharmaceutical Index series focuses on the profiles of 500 pharmaceutically marketed products from the past two decades. Professor Dr. K. Barry Sharpless is Honorary Editor-in-Chief of this first Index by Pharmacodia. The volume includes 24 NCEs worldwide approved drugs in 2013. Pharmacodia plan to publish two further volumes which will feature 2014 NCEs (32 drugs) and 2015 NCEs (25 drugs).

Edited by: Ltd. Pharmacodia (Beijing) Co.
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions: Height: 297mm, Width: 203mm,
Weight: 1.006kg
ISBN: 9781032918846
ISBN 10: 1032918845
Pages: 546
Publication Date: 14 October 2024
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

Executive Summary Chapter 1: Acotiamide Hydrochloride Hydrate Chapter 2: Afatinib Dimaleate Chapter 3: Canagliflozin Hemihydrate Chapter 4: Cetilistat Chapter 5: Cobicistat Chapter 6: Dabrafenib Mesylate. Chapter 7: Dimethyl Fumarate Chapter 8: Dolutegravir Sodium Chapter 9: Efinaconazole Chapter 10: Elvitegravir Chapter 11: Glycerol Phenylbutyrate Chapter 12: Ibrutinib Chapter 13: Istradefylline Chapter 14: Levomilnacipran Hydrochloride Chapter 15: Macitentan Chapter 16: Olodaterol Hydrochloride Chapter 17: Ospemifene Chapter 18: Pomalidomide Chapter 19: Riociguat Chapter 20: Simeprevir Sodium Chapter 21: Sofosbuvir Chapter 22: Topiroxostat Chapter 23: Trametinib Dimethyl Sulfoxide Chapter 24: Vortioxetine Hydrobromide Appendix I. Abbreviation Appendix II. Worldwide Approved NCEs (2001-2014)

Reviews for The Pharmaceutical Index: 2013 Worldwide NCEs

‘This new series of Pharmaceutical Indexes will be a boon in academia and the pharmaceutical industry, and provide, as well, a significant addition to the therapeutics discovery arsenal. It should also find a wide audience in government, and the business community.’ – K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001. ‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’ – James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.